PAVmed Q2 FY26 GAAP net loss narrows to $5.48 million; revenue rises to $33,000

• PAVmed posted GAAP net loss attributable to common stockholders of $5.48 million, or $(0.87) a share, for Q2 2026.
• Operating expenses climbed to $7.06 million; revenue rose to $33,000.
• Non-GAAP adjusted net loss narrowed to $1.67 million, or $(0.27) a share.
• Cash and cash equivalents increased to $3.8 million as of June 30, 2026.
• Veris accelerated OSU-The James onboarding; implantable monitor neared design freeze ahead of early 2027 FDA 510(k) submission.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PAVmed Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608140800PR_NEWS_USPR_____NY26570) on August 14, 2026, and is solely responsible for the information contained therein.